DGAP-Adhoc: Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19
DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19
02-Oct-2019 / 09:13 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19 |
Jena, October 2, 2019
Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,459 million in fiscal year 2018/19 (PY: EUR 1,280.9 million), based on preliminary data, and has thereby significantly exceeded the previous forecast of EUR 1,350 to EUR 1,420 million. This corresponds to revenue growth of approximately 13.9% vs. the previous year's value. After adjustment for currency effects[1], growth amounts to around 11.9 %.
From today's point of view, the company expects a strong increase in operating earnings[2] (EBIT) and anticipates to significantly exceed the previous forecast of an EBIT margin[3] between 15.0% to 17.5% (PY: 15.4%) as well as current market expectations estimated at around 18.5%.
Full results for business year 2018/19 will be provided on Dec 6, 2019.
As already reported after nine months 2018/19, management expects no further sustainable increase in EBIT margin in fiscal year 2019/20, partly due to planned strategic investments in research and development. |
|
Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]
[1] Currency-adjusted sales growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates. [2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation). [3] Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).
02-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Carl Zeiss Meditec AG |
|
Göschwitzer Str. 51-52 |
|
07745 Jena |
|
Germany |
Phone: |
+49 (0)3641 220-0 |
Fax: |
+49 (0)3641 220-112 |
E-mail: |
[email protected] |
Internet: |
www.zeiss.de/meditec-ag/ir |
ISIN: |
DE0005313704 |
WKN: |
531370 |
Indices: |
MDAX, TecDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
884075 |
|
End of Announcement |
DGAP News Service |
884075 02-Oct-2019 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
1.189,90 |
1.280,86 |
1.459,32 |
1.335,45 |
1.646,79 |
1.902,84 |
2.089,30 |
EBITDA1,2 |
205,07 |
228,41 |
313,03 |
237,98 |
435,20 |
466,65 |
422,19 |
EBITDA-Marge3 |
17,23 |
17,83 |
21,45 |
17,82 |
26,43 |
24,52 |
|
EBIT1,4 |
180,83 |
197,13 |
264,66 |
177,55 |
373,61 |
396,88 |
348,12 |
EBIT-Marge5 |
15,20 |
15,39 |
18,14 |
13,30 |
22,69 |
20,86 |
16,66 |
Jahresüberschuss1 |
135,78 |
126,23 |
160,58 |
123,42 |
237,52 |
295,91 |
292,01 |
Netto-Marge6 |
11,41 |
9,86 |
11,00 |
9,24 |
14,42 |
15,55 |
13,98 |
Cashflow1,7 |
37,73 |
187,21 |
219,63 |
178,53 |
362,66 |
188,20 |
250,86 |
Ergebnis je Aktie8 |
1,57 |
1,41 |
1,79 |
1,37 |
2,64 |
3,29 |
3,25 |
Dividende8 |
0,55 |
0,55 |
0,65 |
0,50 |
0,90 |
1,10 |
0,42 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Carl Zeiss Meditec |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
531370 |
97,700 |
Halten |
8.738,34 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
27,52 |
35,03 |
0,79 |
47,89 |
KBV |
KCV |
KUV |
EV/EBITDA |
4,24 |
34,83 |
4,18 |
18,63 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,10 |
1,10 |
1,13 |
21.03.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
09.02.2024 |
08.05.2024 |
06.08.2024 |
12.12.2023 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-11,47% |
1,63% |
-1,15% |
-19,82% |
|
|